After promising in vitro studies which showed success in targeting CD19− escape B-ALL cells, in vivo mouse models were used to investigate the efficacy of CD19/20/22 CAR T cell therapy on targeting CD19+ and CD19− escape malignancies. Here, CD19 is linked to acute lymphoblastic leukemia.